Introduction. Chronic prostatitis (СР) is an inflammation of the prostate tissue, including non-infectious genesis. This is the most common urological disease in men under 50 years of age and the third most common in people over 50 years of age. A promising and actively studied direction of conservative therapy of the inflammatory process in the prostate gland is the use of drugs of animal origin based on prostate extract.

The purpose.This work is devoted to the comparative characteristics of drugs with prostate extract effectiveness in the complex therapy of patients with chronic prostatitis.

Materials and methods. Retrospective analysis of medical records of 125 patients with a previously established diagnosis of СР of the II and IIIA, and IIIB categories aged from 22 to 55 years was performed. Depending on the preparation used with prostate extract in the complex therapy of CP, patients were divided into 5 groups. Preparations with prostate extract were used for 20 days. The effectiveness analysis included an assessment of the dynamics of the clinical picture, the results of laboratory and instrumental research methods, as well as questionnaire data on valid questionnaires I-PSS (International System for the Summary Assessment of Prostate Diseases, Lower Urinary Tract Symptoms (LUTS)), IIEF-15 (International Index of Erectile Function), NIH Chronic Prostatitis symptom Scale- CPSI.

Results. The analysis of the results showed that the use of Vitaprost^® in the complex therapy of СР is accompanied by a decrease in the number of leukocytes in the analysis of prostate secretion, positive dynamics in relation to the total score of the severity of pain syndrome and the patient's assessment of his condition on the NIH-CPSI scale of symptoms of chronic prostatitis, which may indicate a decrease in the inflammatory process in the prostate in general. The effectiveness of therapy in relation to erectile function on the IIEF-15 scale, reduction in the severity of symptoms on the IPSS scale and positive dynamics in relation to urination parameters was also noted.

Conclusion. According to the results of the work carried out, it was the use of Vitaprost^® that was accompanied by a significant decrease in the symptoms of CP and an improvement in the quality of life of patients, as well as erectile function of patients, an increase in the flow rate of urine, a decrease in the volume of residual urine and intensiveness of inflammation.